<p>Zeposia is a medicine used to treat adults with the following diseases:</p><ul><li>relapsing-remitting multiple sclerosis (RRMS). Multiple sclerosis is a disease in which the immune system (the body’s defences) attacks and damages the protective insulation around the nerves and the nerves themselves in the brain and spinal cord. In RRMS, the patient has flare-ups (relapses) followed by periods with milder or no symptoms (remission). Zeposia is used in patients with active disease, which means that patients have relapses or signs of active inflammation on scans;</li><li>ulcerative colitis, a disease causing inflammation and ulcers in the lining of the gut, when the disease is moderately to severely active. Zeposia is used when standard treatment or biological agents (medicines made by cells grown in a laboratory) have not worked well enough or cannot be used by the patient.</li></ul><p>Zeposia contains the active substance ozanimod.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Multiple sclerosis</p> <ul><li>Zeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.</li> </ul><p>Ulcerative colitis</p> <ul><li>Zeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
L04AA38
ATC Item
N/A
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ozanimod hydrochloride | N/A | ozanimod hydrochloride |
EMA Name
Zeposia
Medicine Name
Zeposia
Aliases
N/ANo risk management plan link.
